Literature DB >> 24573016

Reference interval for the apolipoprotein B-48 concentration in healthy Japanese individuals.

Daisaku Masuda1, Makoto Nishida, Toshihiko Arai, Hiroyuki Hanada, Hiroshi Yoshida, Keiko Yamauchi-Takihara, Toshiki Moriyama, Norio Tada, Shizuya Yamashita.   

Abstract

AIM: Small intestine-derived chylomicrons and chylomicron remnants, which are predominant in patients with postprandial hypertriglyceridemia, chylomicron syndrome and/or familial dyslipidemia, carry one molecule of apolipoprotein B-48(apo B-48) per lipoprotein particle. We investigated the reference interval for the apo B-48 concentration.
METHODS: We studied 516 individuals who provided written informed consent and confirmed that they were not taking any medications. BMI, waist circumference, blood pressure and the fasting serum concentrations of LDL-C, triglyceride(TG), HDL-C and apo B-48 were measured. The Apo B-48 concentrations were compared according to sex, a pre- or postmenopausal status, dyslipidemia(LDL-C ≥140 mg/dL, TG ≥150 mg/dL, HDL-C <40 mg/dL), metabolic syndrome(MetS) and the number of risk factors.
RESULTS: The fasting apo B-48 concentrations(mean±SD) were significantly higher in men than in women(3.8±3.3 μg/mL vs 2.4±1.9 μg/mL, p<0.001), subjects with a BMI of ≥25 kg/m(2) versus a BMI of <25 kg/m(2) (4.4±3.7 μg/mL vs 2.8±2.4 μg/mL, p<0.001) and those with versus without MetS(6.5±4.3 μg/mL vs 3.0±2.6 μg/mL, p<0.001). High apo B-48 concentrations were also observed in correlation with the number of risk factors for the MetS. The upper reference limit of apo B-48 was estimated to be 5.7 μg/mL among the 332 patients with normolipidemia, excluding those exhibiting a mean value above ±2.58 standard deviations(SDs), as the mean and range of mean ±1.96 SD were calculated to be 2.04 μg/mL(reference value) and 0.74 to 5.65 μg/mL(reference interval), respectively.
CONCLUSIONS: Based on our study of normolipidemic patients, the upper reference limit for the fasting apo B-48 concentration is estimated to be 5.7 μg/mL.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24573016     DOI: 10.5551/jat.22558

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  5 in total

1.  Effects of a 1-year randomised controlled trial of resistance training on blood lipid profile and chylomicron concentration in older men.

Authors:  Anthony P James; Joanna Whiteford; Timothy R Ackland; Satvinder S Dhaliwal; Jenni J Woodhouse; Richard L Prince; Xingqiong Meng; Deborah A Kerr
Journal:  Eur J Appl Physiol       Date:  2016-09-02       Impact factor: 3.078

2.  Enhanced Impact of Cholesterol Absorption Marker on New Atherosclerotic Lesion Progression After Coronary Intervention During Statin Therapy.

Authors:  Kenta Mori; Tatsuro Ishida; Shigeyasu Tsuda; Toshihiko Oshita; Masakazu Shinohara; Tetsuya Hara; Yasuhiro Irino; Ryuji Toh; Ken-Ichi Hirata
Journal:  J Atheroscler Thromb       Date:  2016-08-04       Impact factor: 4.928

3.  Plasma triglyceride and high density lipoprotein cholesterol are poor surrogate markers of pro-atherogenic chylomicron remnant homeostasis in subjects with the metabolic syndrome.

Authors:  Deasy Irawati; John C L Mamo; Satvinder S Dhaliwal; Mario J Soares; Karin M Slivkoff-Clark; Anthony P James
Journal:  Lipids Health Dis       Date:  2016-09-29       Impact factor: 3.876

Review 4.  Postprandial Hyperlipidemia and Remnant Lipoproteins.

Authors:  Daisaku Masuda; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2016-11-08       Impact factor: 4.928

5.  Postprandial Hyperlipidemia: Association with Inflammation and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis.

Authors:  Natalia Mena-Vázquez; Rocío Redondo-Rodríguez; José Rioja; Francisco Gabriel Jimenez-Nuñez; Sara Manrique-Arija; Jose Manuel Lisbona-Montañez; Laura Cano-García; Marta Rojas-Gimenez; Inmaculada Ureña; Pedro Valdivielso; Antonio Fernández-Nebro
Journal:  Biomedicines       Date:  2022-01-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.